Gene News and Research

Latest Gene News and Research

Positive data from Lexicon LX1032 Phase 2 study on carcinoid syndrome

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line proof-of-concept data from its recently completed Phase 2 study in carcinoid syndrome with LX1032, telotristat etiprate. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract.

9 Aug 2011

Researchers clarify role of two proteins key to T-cell development

In the latest issue of Nature, researchers at the Perelman School of Medicine at the University of Pennsylvania clarify the role of two proteins key to T-cell development.

9 Aug 2011

Lentiviral vector can kill HIV-infected cells

In what represents an important step toward curing HIV, a USC scientist has created a virus that hunts down HIV-infected cells.

9 Aug 2011

Criterium to manage Senesco's SNS01-T Phase Ib/2a multiple myeloma study

Senesco Technologies, Inc. today announced that it has contracted Criterium, Inc. to manage the operational aspects of its Phase Ib/2a clinical study of SNS01-T, the Company's lead therapeutic candidate for the treatment of multiple myeloma.

9 Aug 2011

Lexicon's second quarter revenues decrease 55% to $0.6 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.

9 Aug 2011

Genetically altered spermless ‘mozzies’ to combat malaria

In a fresh new attempt to combat malaria, researchers have developed another way to reduce the numbers of the malaria-spreading blood-suckers: introduce genetically altered spermless males into the population.

8 Aug 2011

HUYA enters strategic partnership with King's Lab

HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovations, today announced a strategic partnership with the Shanghai Jiao Tong University School of Pharmacy King's Lab. The alliance with HUYA will assist King's Lab in accelerating the development of their novel drugs to international standards.

8 Aug 2011

Response Genetics second quarter total revenue increases 18.8% to $6.7 million

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results and business progress for the second quarter ended June 30, 2011.

8 Aug 2011

Researchers discover gene variant linked to meningiomas

The causes of brain tumours have been hard to discern in most cases. But Umeå researchers have previously identified an inherited predisposition for brain tumours, and now, in an international collaboration, they have also discovered a genetic variation that increases the risk of a certain type of brain tumour, called meningiomas.

8 Aug 2011

Affymetrix announces commercialization of next-generation human transcriptome array

Affymetrix, Inc. today announced commercialization of the next-generation human transcriptome array demonstrated by Stanford University researchers to be superior to mRNA sequencing (RNA-Seq) in gene expression profiling studies.

8 Aug 2011

Schizophrenia not always inherited – Genetic links found

Researchers have found that more than half the cases of non-hereditary or sporadic schizophrenia are caused by “new” protein-altering gene mutations. These mutations are new genetic errors that appear in patients but not in either of their parents, the researchers explained in the report published in the Aug. 7 online edition of the journal Nature Genetics.

8 Aug 2011

Ovarian cancer gene discovered

A new study finds that around one woman in 70 is at risk of developing ovarian cancer, which claims more than 4,200 lives a year and this could be attributed to a faulty RAD15D gene. The gene raised the risk to one in 11.

8 Aug 2011

NHS doctors’ use of genetic tests leading to infringement of patent rights

NHS doctors are in trouble for over use of diagnostic genetic tests as these infringe upon patents. The British law now recognizes patents on the application of DNA discoveries. But doctors developing genetic tests in NHS hospitals tend to pay no heed to intellectual property.

8 Aug 2011

Researchers use SNAP technology to assess fetal gene expression in amniotic fluid

Researchers have demonstrated the feasibility of focused fetal gene expression analysis of target genes found in amniotic fluid using Standardized NanoArray PCR (SNAP) technology.

8 Aug 2011

De novo mutations account for 50% of sporadic cases of schizophrenia

Columbia University Medical Center researchers have shown that new, or "de novo," protein-altering mutations—genetic errors that are present in patients but not in their parents—play a role in more than 50 percent of "sporadic" —i.e., not hereditary—cases of schizophrenia.

8 Aug 2011

New finding about cell metabolism may have implications for neurodegenerative disorders

Cells are the building blocks of the human body. They are a focus of scientific study, because when things go wrong at the cellular and molecular level the consequences for human health are often significant.

8 Aug 2011

Women with RAD51D gene fault more likely to develop ovarian cancer

Cancer Research UK-funded scientists have discovered that women who carry a faulty copy of a gene called RAD51D have almost a one in 11 chance of developing ovarian cancer, the most significant ovarian cancer gene discovery for more than a decade, reveals a study in Nature Genetics1 today.

8 Aug 2011

Scientist urges federal officials to decide on genetically engineered salmon for consumption

A Purdue University scientist is urging federal officials to decide whether genetically engineered salmon would be allowed for U.S. consumption and arguing that not doing so may set back scientific efforts to increase food production.

6 Aug 2011

Idera second quarter net loss increases to $6.3 million

Idera Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like receptors (TLRs).

5 Aug 2011

Novel studies explore new targets to prevent spread of breast cancer

Research into new methods to prevent and slow metastatic breast cancer will be presented this week at the Era of Hope conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program.

5 Aug 2011